- TriLink BioTechnologies has partnered with Avantor to expand the availability of its nucleic acid products in Europe, the Middle East, and Africa (EMEA).
- The partnership aims to streamline ordering, reduce lead times, and support growing demand for nucleic acid-based research and therapeutics.
TriLink BioTechnologies, a Maravai LifeSciences company, has announced a partnership with Avantor to distribute its nucleic acid products across Europe, the Middle East, and Africa (EMEA). The collaboration aims to enhance product availability, improve ordering efficiency, and reduce lead times for European customers.
With over 25 years of experience in nucleic acid product development and manufacturing, TriLink specializes in mRNA-based therapeutic innovations. Through this agreement, its products—including CleanCap cap analogs, catalog mRNAs, nucleotides, and IVT enzymes—will become more accessible in EMEA markets. These products will also be available on Avantor’s VWR eCommerce platform, MarketSource, in the coming months.
“This partnership marks an important step in expanding access to our cutting-edge nucleic acid technologies across Europe,” said Becky Buzzeo, Chief Commercial Officer at TriLink. “By collaborating with a trusted partner like Avantor and leveraging their unmatched distribution network, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research.”
The company provides high-quality technology and CDMO services for nucleic acid therapeutics, vaccines, and diagnostics. Its growing portfolio includes mRNA capping analogs, raw materials such as nucleotides and IVT enzymes, and expertise in mRNA, oligonucleotide, and enzyme production. Through the partnership, TriLink aims to support researchers and developers with streamlined access to critical reagents and manufacturing capabilities.